Cyclodextrin-based delivery systems for cancer treatment.
Cancer treatment
Chemotherapy drugs
Cyclodextrin-based delivery system
Genetic therapeutic agents
Intelligent
Precise release
Targeting
Journal
Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
01
04
2018
revised:
09
10
2018
accepted:
22
11
2018
entrez:
5
1
2019
pubmed:
5
1
2019
medline:
13
3
2019
Statut:
ppublish
Résumé
Cyclodextrins, one of safe excipients, are able to form host-guest complexes with fitted molecules given the unique nature imparted by their structure in result of a number of pharmaceutical applications. On the other hand, targeted or responsive materials are appealing therapeutic platforms for the development of next-generation precision medications. Meanwhile, cyclodextrin-based polymers or assemblies can condense DNA and RNA in result to be used as genetic therapeutic agents. Armed with a better understanding of various pharmaceutical mechanisms, especially for cancer treatment, researchers have made lots of works about cyclodextrin-based drug delivery systems in materials chemistry and pharmaceutical science. This Review highlights recent advances in cyclodextrin-based delivery systems for cancer treatment capable of targeting or responding to the physiological environment. Key design principles, challenges and future directions, including clinical translation, of cyclodextrin-based delivery systems are also discussed.
Identifiants
pubmed: 30606602
pii: S0928-4931(18)30947-0
doi: 10.1016/j.msec.2018.11.031
pii:
doi:
Substances chimiques
Cyclodextrins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
872-886Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.